Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment

Alzheimer disease (AD) is a devastating disease and a global health problem, and current treatments are only symptomatic. A wealth of clinical studies support that the disease starts to develop decades before the first symptoms appear, emphasizing the importance of studying early changes for improvi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schedin‐Weiss, Sophia, Gaunitz, Stefan, Sui, Ping, Chen, Qiushi, Haslam, Stuart M., Blennow, Kaj, Winblad, Bengt, Dell, Anne, Tjernberg, Lars O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496940/
https://www.ncbi.nlm.nih.gov/pubmed/31889402
http://dx.doi.org/10.1111/febs.15197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496940/
https://www.ncbi.nlm.nih.gov/pubmed/31889402
http://dx.doi.org/10.1111/febs.15197

Ejemplares similares